Editas Medicine reported a quarterly loss of $0.26 per share, narrower than the Zacks Consensus Estimate for a $0.30 loss and improved from a $0.43 loss a year ago. The result is a modest earnings beat, but the article provides no revenue or guidance details. The news is likely to be modestly supportive for the stock rather than sector-moving.
Editas Medicine reported a quarterly loss of $0.26 per share, narrower than the Zacks Consensus Estimate for a $0.30 loss and improved from a $0.43 loss a year ago. The result is a modest earnings beat, but the article provides no revenue or guidance details. The news is likely to be modestly supportive for the stock rather than sector-moving.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
